Zubsolv market share (rolling 4 weeks average) was lower in April compared to the March numbers. In the last week of April (ending 26 of April) Zubsolv prescription recorded a market share of 5.25%, down by 0.17% from March. The market share, estimated as number of units, reached 5,39% at the end of April, down by 0.08% from last month. The market for buprenorphine/naloxone products continues to show strong underlying growth, with a y/y growth rate of 10.6% (TRx) and 9.4% (units), on a monthly basis, at the end of April.